Complement and spinal cord injury: Traditional and non-traditional aspects of complement cascade function in the injured spinal cord microenvironment

Experimental Neurology

Volumn 258, Issue , 2014, Pages 35-47

  Peterson, Sheri L ^a,b   Anderson, Aileen J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Axon; C1q; C3; Complement; Guidance; Inflammation; Regeneration; Scar; Spinal cord injury

Indexed keywords

COMPLEMENT; PROTEIN;

CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MICROENVIRONMENT; NERVOUS SYSTEM INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY;

AXON; C1Q; C3; COMPLEMENT; GUIDANCE; INFLAMMATION; REGENERATION; SCAR; SPINAL CORD INJURY;

ANIMALS; CELL MOVEMENT; CELLULAR MICROENVIRONMENT; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; RECOVERY OF FUNCTION; SPINAL CORD INJURIES;

EID: 84904730509     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.04.028     Document Type: Review

References (192)

1. Alexander J.J., Anderson A.J., Barnum S.R., Stevens B., Tenner A.J. The complement cascade: yin-yang in neuroinflammation-neuro-protection and -degeneration. J. Neurochem. 2008, 107:1169-1187.
2. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
3. Anderson A. Neuropathological Correlate of Non-traditional C5 Cleavage in Spinal Cord Injured C3-Deficient Mice 2014, (submitted for publication).
4. Anderson A.J., Robert S., Huang W., Young W., Cotman C.W. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 2004, 21:1831-1846.
5. Anderson A.J., Najbauer J., Huang W., Young W., Robert S. Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury. J. Neurotrauma 2005, 22:382-397.
6. Ankeny D.P., Popovich P.G. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009, 158:1112-1121.
7. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J. Clin. Invest. 2009, 119:2990-2999.
8. Armstrong R.C., Harvath L., Dubois-Dalcq M.E. Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules. J. Neurosci. Res. 1990, 27:400-407.
9. Barnum S.R. Complement biosynthesis in the central nervous system. Crit. Rev. Oral Biol. Med. 1995, 6:132-146.
10. Beattie M.S., Hermann G.E., Rogers R.C., Bresnahan J.C. Cell death in models of spinal cord injury. Prog. Brain Res. 2002, 137:37-47.
11. Beck K.D., Nguyen H.X., Galvan M.D., Salazar D.L., Woodruff T.M., Anderson A.J. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010, 133:433-447.
12. Beggs J.L., Waggener J.D. Vasogenic edema in the injured spinal cord: a method of evaluating the extent of blood-brain barrier alteration to horseradish peroxidase. Exp. Neurol. 1975, 49:86-96.
13. Benard M., Gonzalez B.J., Schouft M.T., Falluel-Morel A., Vaudry D., Chan P., Vaudry H., Fontaine M. Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J. Biol. Chem. 2004, 279:43487-43496.
14. Benard M., Raoult E., Vaudry D., Leprince J., Falluel-Morel A., Gonzalez B.J., Galas L., Vaudry H., Fontaine M. Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Mol. Immunol. 2008, 45:3767-3774.
15. Benoit M.E., Tenner A.J. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J. Neurosci. 2011, 31:3459-3469.
16. Benoit M.E., Clarke E.V., Morgado P., Fraser D.A., Tenner A.J. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J. Immunol. 2012, 188:5682-5693.
17. Berg A., Zelano J., Stephan A., Thams S., Barres B.A., Pekny M., Pekna M., Cullheim S. Reduced removal of synaptic terminals from axotomized spinal motoneurons in the absence of complement C3. Exp. Neurol. 2012, 237:8-17.
18. Blaber S.I., Scarisbrick I.A., Bernett M.J., Dhanarajan P., Seavy M.A., Jin Y., Schwartz M.A., Rodriguez M., Blaber M. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 2002, 41:1165-1173.
19. Blight A.R. Macrophages and inflammatory damage in spinal cord injury. J. Neurotrauma 1992, 9(Suppl. 1):S83-S91.
20. Bogestal Y.R., Barnum S.R., Smith P.L., Mattisson V., Pekny M., Pekna M. Signaling through C5aR is not involved in basal neurogenesis. J. Neurosci. Res. 2007, 85:2892-2897.
21. Bohana-Kashtan O., Ziporen L., Donin N., Kraus S., Fishelson Z. Cell signals transduced by complement. Mol. Immunol. 2004, 41:583-597.
22. Bohlson S.S., Fraser D.A., Tenner A.J. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol. Immunol. 2007, 44:33-43.
23. Bokisch V.A., Dierich M.P., Muller-Eberhard H.J. Third component of complement (C3): structural properties in relation to functions. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:1989-1993.
24. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 2007, 44:999-1010.
25. Bradbury E.J., Moon L.D., Popat R.J., King V.R., Bennett G.S., Patel P.N., Fawcett J.W., McMahon S.B. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416:636-640.
26. Bramlett H.M., Dietrich W.D. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog. Brain Res. 2007, 161:125-141.
27. Bruck W., Friede R.L. Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro. Acta Neuropathol. 1990, 80:415-418.
28. Bruck W., Friede R.L. The role of complement in myelin phagocytosis during PNS wallerian degeneration. J. Neurol. Sci. 1991, 103:182-187.
29. Bruck W., Bruck Y., Diederich U., Piddlesden S.J. The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol. 1995, 90:601-607.
30. Bucky Jones T. Lymphocytes and autoimmunity after spinal cord injury. Experimental Neurology 2014, 258:78-90. (in this issue).
31. Carlson S.L., Parrish M.E., Springer J.E., Doty K., Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp. Neurol. 1998, 151:77-88.
32. Chen A., Gaddipati S., Hong Y., Volkman D.J., Peerschke E.I., Ghebrehiwet B. Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation. J. Immunol. 1994, 153:1430-1440.
33. Chu Y., Jin X., Parada I., Pesic A., Stevens B., Barres B., Prince D.A. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7975-7980.
34. Cole D.S., Morgan B.P. Beyond lysis: how complement influences cell fate. Clin. Sci. (Lond.) 2003, 104:455-466.
35. Cui W., Paglialunga S., Kalant D., Lu H., Roy C., Laplante M., Deshaies Y., Cianflone K. Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1482-E1491.
36. Dailey A.T., Avellino A.M., Benthem L., Silver J., Kliot M. Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J. Neurosci. 1998, 18:6713-6722.
37. Daveau M., Benard M., Scotte M., Schouft M.T., Hiron M., Francois A., Salier J.P., Fontaine M. Expression of a functional C5a receptor in regenerating hepatocytes and its involvement in a proliferative signaling pathway in rat. J. Immunol. 2004, 173:3418-3424.
38. Davis A.E., Lu F., Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost. 2010, 104:886-893.
39. DeAngelis R.A., Markiewski M.M., Kourtzelis I., Rafail S., Syriga M., Sandor A., Maurya M.R., Gupta S., Subramaniam S., Lambris J.D. A complement-IL-4 regulatory circuit controls liver regeneration. J. Immunol. 2012, 188:641-648.
40. Del Rio-Tsonis K., Tsonis P.A., Zarkadis I.K., Tsagas A.G., Lambris J.D. Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. J. Immunol. 1998, 161:6819-6824.
41. Donaldson V.H., Evans R.R. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-esterase. Am. J. Med. 1963, 35:37-44.
42. Duce J.A., Hollander W., Jaffe R., Abraham C.R. Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain. Neurobiol. Aging 2006, 27:633-644.
43. Dyer J.K., Bourque J.A., Steeves J.D. Regeneration of brainstem-spinal axons after lesion and immunological disruption of myelin in adult rat. Exp. Neurol. 1998, 154:12-22.
44. Edwards S., Morgan B., Hoy T., Luzio J., Campbell A. Complement-mediated lysis of pigeon erythrocyte ghosts analysed by flow cytometry. Evidence for the involvement of a 'threshold' phenomenon. Biochem. J. 1983, 216:195-202.
45. Eggleton P., Tenner A.J., Reid K.B. C1q receptors. Clin. Exp. Immunol. 2000, 120:406-412.
46. Ehrnthaller C., Ignatius A., Gebhard F., Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol. Med. 2011, 17:317-329.
47. Fan R., Tenner A.J. Complement C1q expression induced by Aβ in rat hippocampal organotypic slice cultures. Exp. Neurol. 2004, 185:241-253.
48. Fawcett J.W., Asher R.A. The glial scar and central nervous system repair. Brain Res. Bull. 1999, 49:377-391.
49. Fitch M.T., Doller C., Combs C.K., Landreth G.E., Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci. 1999, 19:8182-8198.
50. Fleming J.C., Norenberg M.D., Ramsay D.A., Dekaban G.A., Marcillo A.E., Saenz A.D., Pasquale-Styles M., Dietrich W.D., Weaver L.C. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
51. Gadjeva M.G., Rouseva M.M., Zlatarova A.S., Reid K.B., Kishore U., Kojouharova M.S. Interaction of human C1q with IgG and IgM: revisited. Biochemistry 2008, 47:13093-13102.
52. Galvan M.D., Luchetti S., Burgos A.M., Nguyen H.X., Hooshmand M.J., Hamers F.P., Anderson A.J. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J. Neurosci. 2008, 28:13876-13888.
53. Gasque P., Fontaine M., Morgan B.P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 1995, 154:4726-4733.
54. Ghebrehiwet B., Habicht G.S., Beck G. Interaction of C1q with its receptor on cultured cell lines induces an anti-proliferative response. Clin. Immunol. Immunopathol. 1990, 54:148-160.
55. Ghebrehiwet B., Feng X., Kumar R., Peerschke E.I.B. Complement component C1q induces endothelial cell adhesion and spreading through a docking/signaling partnership of C1q receptors and integrins. Int. Immunopharmacol. 2003, 3:299-310.
56. Goodman J.H., Bingham W.G., Hunt W.E. Ultrastructural blood-brain barrier alterations and edema formation in acute spinal cord trauma. J. Neurosurg. 1976, 44:418-424.
57. Guo Q., Li S., Liang Y., Zhang Y., Zhang J., Wen C., Lin S., Wang H., Su B. Effects of C3 deficiency on inflammation and regeneration following spinal cord injury in mice. Neurosci. Lett. 2010, 485:32-36.
58. Harboe M., Ulvund G., Vien L., Fung M., Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138:439-446.
59. Hawthorne A.L., Popovich P.G. Emerging concepts in myeloid cell biology after spinal cord injury. Neurotherapeutics 2011, 8:252-261.
60. Haynes T., Luz-Madrigal A., Reis E.S., Echeverri Ruiz N.P., Grajales-Esquivel E., Tzekou A., Tsonis P.A., Lambris J.D., Del Rio-Tsonis K. Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nat. Commun. 2013, 4:2312.
61. Heese K., Hock C., Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J. Neurochem. 1998, 70:699-707.
62. Hoarau J.J., Krejbich-Trotot P., Jaffar-Bandjee M.C., Das T., Thon-Hon G.V., Kumar S., Neal J.W., Gasque P. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol. Disord. Drug Targets 2011, 10:25-43.
63. Hooshmand M., Galvan M.D., Kamei N., Su D., Burgos A., Lucero J., Anderson A. The complexity of complement: a dynamic and dual role for C6 deficiency following spinal cord injury 2014, (submitted for publication).
64. Hooshmand M., Nguyen H.X., Hong S., Uchida N., Tamaki S., Cummings B., Anderson A. Complement proteins C1q and C3a promote migration and astroglial differentiation of human neural stem cells 2014, (submitted for publication).
65. Hosokawa M., Klegeris A., Maguire J., McGeer P.L. Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 2003, 42:417-423.
66. Huang J.K., Franklin R.J. Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation. Neurochem. Int. 2011, 59:329-332.
67. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
68. Huey R., Bloor C., Kawahara M., Hugli T. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am. J. Pathol. 1983, 112:48-60.
69. Hunt D., Coffin R.S., Anderson P.N. The Nogo receptor, its ligands and axonal regeneration in the spinal cord; a review. J. Neurocytol. 2002, 31:93-120.
70. Janeway C. Immunobiology 2001, Garland Publishing, New York, New York. 5 ed.
71. Janowska-Wieczorek A., Marquez-Curtis L.A., Shirvaikar N., Ratajczak M.Z. The role of complement in the trafficking of hematopoietic stem/progenitor cells. Transfusion 2012, 52:2706-2716.
72. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
73. Jauneau A.C., Ischenko A., Chatagner A., Benard M., Chan P., Schouft M.T., Patte C., Vaudry H., Fontaine M. Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J. Neuroinflammation 2006, 3:8.
74. Jegou J.F., Chan P., Schouft M.T., Griffiths M.R., Neal J.W., Gasque P., Vaudry H., Fontaine M. C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:3323-3331.
75. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 1994, 152:5050-5059.
76. Johns T.G., Bernard C.C. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 1997, 34:33-38.
77. Johswich K., Klos A. C5L2-an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)?. Adv. Exp. Med. Biol. 2007, 598:159-180.
78. Keirstead H.S., Hughes H.C., Blakemore W.F. A quantifiable model of axonal regeneration in the demyelinated adult rat spinal cord. Exp. Neurol. 1998, 151:303-313.
79. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 2009, 29:13435-13444.
80. Kilgore K., Ward P., Warren J. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation 1998, 22:583-598.
81. Kimura Y., Madhavan M., Call M.K., Santiago W., Tsonis P.A., Lambris J.D., Del Rio-Tsonis K. Expression of complement 3 and complement 5 in newt limb and lens regeneration. J. Immunol. 2003, 170:2331-2339.
82. Kishore U., Reid K.B. C1q: structure, function, and receptors. Immunopharmacology 2000, 49:159-170.
83. Kjaer T.R., Thiel S., Andersen G.R. Toward a structure-based comprehension of the lectin pathway of complement. Mol. Immunol. 2013, 56:413-422.
84. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
85. Klos A., Wende E., Wareham K.J., Monk P.N. International union of pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 2013, 65:500-543.
86. Kolev M.V., Tediose T., Sivasankar B., Harris C.L., Thome J., Morgan B.P., Donev R.M. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J. 2010, 10:12-19.
87. Koski C.L., Estep A.E., Sawant-Mane S., Shin M.L., Highbarger L., Hansch G.M. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J. Neurochem. 1996, 66:303-312.
88. Kossmann T., Stahel P.F., Morganti-Kossmann M.C., Jones J.L., Barnum S.R. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J. Neuroimmunol. 1997, 73:63-69.
89. Krumdieck R., Hook M., Rosenberg L.C., Volanakis J.E. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J. Immunol. 1992, 149:3695-3701.
90. Kuehn M.H., Kim C.Y., Jiang B., Dumitrescu A.V., Kwon Y.H. Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion. Exp. Eye Res. 2008, 87:89-95.
91. Laursen N.S., Magnani F., Gottfredsen R.H., Petersen S.V., Andersen G.R. Structure, function and control of complement C5 and its proteolytic fragments. Curr. Mol. Med. 2012, 12:1083-1097.
92. Levi-Strauss M., Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J. Immunol. 1987, 139:2361-2366.
93. Li L., Li J., Zhu Y., Fan G. Ephedra sinica inhibits complement activation and improves the motor functions after spinal cord injury in rats. Brain Res. Bull. 2009, 78:261-266.
94. Li L.M., Li J.B., Zhu Y., Fan G.Y. Soluble complement receptor type 1 inhibits complement system activation and improves motor function in acute spinal cord injury. Spinal Cord 2010, 48:105-111.
95. Liu L., Persson J.K., Svensson M., Aldskogius H. Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. Glia 1998, 23:221-238.
96. Luchetti S., Beck K.D., Galvan M.D., Silva R., Cummings B.J., Anderson A.J. Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury. J. Neurotrauma 2010, 27:411-421.
97. Makrides S.C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 1998, 50:59-87.
98. Mastellos D. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol. Immunol. 2004, 40:1213-1221.
99. Mastellos D., Papadimitriou J.C., Franchini S., Tsonis P.A., Lambris J.D. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 2001, 166:2479-2486.
100. Matthews K.W., Mueller-Ortiz S.L., Wetsel R.A. Carboxypeptidase N: a pleiotropic regulator of inflammation. Mol. Immunol. 2004, 40:785-793.
101. Mautes A.E., Weinzierl M.R., Donovan F., Noble L.J. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys. Ther. 2000, 80:673-687.
102. McGrath F., Brouwer M., Arlaud G., Daha M., Hack C., Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J. Immunol. 2006, 176:2950-2957.
103. McTigue D.M., Popovich P.G., Jakeman L.B., Stokes B.T. Strategies for spinal cord injury repair. Prog. Brain Res. 2000, 128:3-8.
104. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 2002, 168:458-465.
105. Morgan B.P., Gasque P. Extrahepatic complement biosynthesis: where, when and why?. Clin. Exp. Immunol. 1997, 107:1-7.
106. Moriyama M., Fukuhara T., Britschgi M., He Y., Narasimhan R., Villeda S., Molina H., Huber B.T., Holers M., Wyss-Coray T. Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J. Neurosci. 2011, 31:3981-3989.
107. Mukherjee P., Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 2001, 77:43-49.
108. Muller-Eberhard H.J. The killer molecule of complement. J. Invest. Dermatol. 1985, 85:47s-52s.
109. Nataf S., Stahel P.F., Davoust N., Barnum S.R. Complement anaphylatoxin receptors on neurons: new tricks for old receptors?. Trends Neurosci. 1999, 22:397-402.
110. Nataf S., Levison S.W., Barnum S.R. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 2001, 894:321-326.
111. Nauta A.J., Bottazzi B., Mantovani A., Salvatori G., Kishore U., Schwaeble W.J., Gingras A.R., Tzima S., Vivanco F., Egido J., Tijsma O., Hack E.C., Daha M.R., Roos A. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur. J. Immunol. 2003, 33:465-473.
112. Nguyen H.X., Galvan M.D., Anderson A.J. Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury. J. Neuroinflammation 2008, 5:26.
113. Noble L.J., Maxwell D.S. Blood-spinal cord barrier response to transection. Exp. Neurol. 1983, 79:188-199.
114. Ohlsson M., Havton L.A. Complement activation after lumbosacral ventral root avulsion injury. Neurosci. Lett. 2006, 394:179-183.
115. Ohno M., Hirata T., Enomoto M., Araki T., Ishimaru H., Takahashi T. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 2000, 37:407-412.
116. Ong G.L., Mattes M.J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods 1989, 125:147-158.
117. Osaka H., Mukherjee P., Aisen P.S., Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 1999, 73:303-311.
118. Osmers I., Szalai A.J., Tenner A.J., Barnum S.R. Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol. Immunol. 2006, 43:1722-1725.
119. Pangburn M.K., Rawal N. Structure and function of complement C5 convertase enzymes. Biochem. Soc. Trans. 2002, 30:1006-1010.
120. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 1981, 154:856-867.
121. Pavlovski D., Thundyil J., Monk P.N., Wetsel R.A., Taylor S.M., Woodruff T.M. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 2012, 26:3680-3690.
122. Peterson S., Nguyen H.X., Mendez O., Anderson A. Complement protein C3 decreases axon growth in vitro and in vivo 2014, (submitted for publication).
123. Peterson S., Nguyen H.X., Mendez O., Anderson A. Complement Protein C1q Modulates Neurite Outgrowth In Vitro and Spinal Cord Axon Regeneration In Vivo 2014, (submitted for publication).
124. Pfarr N., Prawitt D., Kirschfink M., Schroff C., Knuf M., Habermehl P., Mannhardt W., Zepp F., Fairbrother W.G., Loos M., Burge C.B., Pohlenz J. Linking C5 deficiency to an exonic splicing enhancer mutation. J. Immunol. 2005, 174:4172-4177.
125. Piddlesden S.J., Morgan B.P. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J. Neuroimmunol. 1993, 48:169-175.
126. Popovich P.G., Horner P.J., Mullin B.B., Stokes B.T. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 1996, 142:258-275.
127. Popovich P.G., Wei P., Stokes B.T. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 1997, 377:443-464.
128. Pruss H., Kopp M.A., Brommer B., Gatzemeier N., Laginha I., Dirnagl U., Schwab J.M. Non-resolving aspects of acute inflammation after spinal cord injury (SCI): indices and resolution plateau. Brain Pathol. 2011, 21:652-660.
129. Qiao F., Atkinson C., Song H., Pannu R., Singh I., Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 2006, 169:1039-1047.
130. Qiao F., Atkinson C., Kindy M.S., Shunmugavel A., Morgan B.P., Song H., Tomlinson S. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am. J. Pathol. 2010, 177:3061-3070.
131. Raedler H., Heeger P.S. Complement regulation of T-cell alloimmunity. Curr. Opin. Organ Transplant. 2011, 16:54-60.
132. Rahpeymai Y., Hietala M.A., Wilhelmsson U., Fotheringham A., Davies I., Nilsson A.K., Zwirner J., Wetsel R.A., Gerard C., Pekny M., Pekna M. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 2006, 25:1364-1374.
133. Ramaglia V., King R.H., Nourallah M., Wolterman R., de Jonge R., Ramkema M., Vigar M.A., van der Wetering S., Morgan B.P., Troost D., Baas F. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J. Neurosci. 2007, 27:7663-7672.
134. Ramos T.N., Darley M.M., Weckbach S., Stahel P.F., Tomlinson S., Barnum S.R. The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J. Biol. Chem. 2012, 287:24734-24738.
135. Rebhun J., Botvin J. Complement elevation in spinal cord injury. Ann. Allergy 1980, 44:287-288.
136. Rebhun J., Botvin Madorsky J.G. Spinal cord injury: diagnostic indicators. Arch. Phys. Med. Rehabil. 1983, 64:329-330.
137. Rebhun J., Madorsky J.G., Glovsky M.M. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann. Allergy 1991, 66:335-338.
138. Reca R., Mastellos D., Majka M., Marquez L., Ratajczak J., Franchini S., Glodek A., Honczarenko M., Spruce L.A., Janowska-Wieczorek A., Lambris J.D., Ratajczak M.Z. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003, 101:3784-3793.
139. Renault-Mihara F., Okada S., Shibata S., Nakamura M., Toyama Y., Okano H. Spinal cord injury: emerging beneficial role of reactive astrocytes' migration. Int. J. Biochem. Cell Biol. 2008, 40:1649-1653.
140. Reynolds D.N., Smith S.A., Zhang Y.P., Mengsheng Q., Lahiri D.K., Morassutti D.J., Shields C.B., Kotwal G.J. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann. N. Y. Acad. Sci. 2004, 1035:165-178.
141. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 2013, 735:1-22.
142. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
143. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10016-10020.
144. Rolls A., Shechter R., Schwartz M. The bright side of the glial scar in CNS repair. Nat. Rev. Neurosci. 2009, 10:235-241.
145. Roos A., Ramwadhdoebe T.H., Nauta A.J., Hack C.E., Daha M.R. Therapeutic inhibition of the early phase of complement activation. Immunobiology 2002, 205:595-609.
146. Ross G.D., Lambris J.D., Cain J.A., Newman S.L. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J. Immunol. 1982, 129:2051-2060.
147. Roumenina L.T., Ruseva M.M., Zlatarova A., Ghai R., Kolev M., Olova N., Gadjeva M., Agrawal A., Bottazzi B., Mantovani A., Reid K.B., Kishore U., Kojouharova M.S. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006, 45:4093-4104.
148. Rus H.G., Niculescu F., Shin M.L. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 1996, 156:4892-4900.
149. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Fang S., Parsa A.T. Complement and the central nervous system: emerging roles in development, protection and regeneration. Immunol. Cell Biol. 2010, 88:781-786.
150. Sahu A., Lambris J.D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000, 49:133-148.
151. Sahu A., Lambris J. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 2001, 180:35-48.
152. Schafer D.P., Lehrman E.K., Kautzman A.G., Koyama R., Mardinly A.R., Yamasaki R., Ransohoff R.M., Greenberg M.E., Barres B.A., Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
153. Scolding N.J., Morgan B.P., Compston D.A. The expression of complement regulatory proteins by adult human oligodendrocytes. J. Neuroimmunol. 1998, 84:69-75.
154. Shinjyo N., Stahlberg A., Dragunow M., Pekny M., Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 2009, 27:2824-2832.
155. Soane L., Rus H., Niculescu F., Shin M. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 1999, 163:6132-6138.
156. Soderblom C., Luo X., Blumenthal E., Bray E., Lyapichev K., Ramos J., Krishnan V., Lai-Hsu C., Park K.K., Tsoulfas P., Lee J.K. Perivascular fibroblasts form the fibrotic scar after contusive spinal cord injury. J. Neurosci. 2013, 33:13882-13887.
157. Stanley K., Page M., Campbell A., Luzio J. A mechanism for the insertion of complement component C9 into target membranes. Mol. Immunol. 1986, 23:451-458.
158. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., Micheva K.D., Mehalow A.K., Huberman A.D., Stafford B., Sher A., Litke A.M., Lambris J.D., Smith S.J., John S.W., Barres B.A. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
159. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R., Heeger P.S., Medof M.E. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435.
160. Strey C.W., Markiewski M., Mastellos D., Tudoran R., Spruce L.A., Greenbaum L.E., Lambris J.D. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J. Exp. Med. 2003, 198:913-923.
161. Suetsugu-Maki R., Maki N., Fox T.P., Nakamura K., Cowper Solari R., Tomlinson C.R., Qu H., Lambris J.D., Tsonis P.A. A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. Mol. Vis. 2011, 17:949-964.
162. Sun X., Wang X., Chen T., Li T., Cao K., Lu A., Chen Y., Sun D., Luo J., Fan J., Young W., Ren Y. Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS One 2010, 5:e9380.
163. Tahtouh M., Croq F., Vizioli J., Sautiere P.E., Van Camp C., Salzet M., Daha M.R., Pestel J., Lefebvre C. Evidence for a novel chemotactic C1q domain-containing factor in the leech nerve cord. Mol. Immunol. 2009, 46:523-531.
164. Takahashi C., Muramatsu R., Fujimura H., Mochizuki H., Yamashita T. Prostacyclin promotes oligodendrocyte precursor recruitment and remyelination after spinal cord demyelination. Cell Death Dis. 2013, 4:e795.
165. Tegla C.A., Cudrici C., Patel S., Trippe R., Rus V., Niculescu F., Rus H. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 2011, 51:45-60.
166. Tei R., Kaido T., Nakase H., Sakaki T. Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat. Neurol. Res. 2008, 30:761-767.
167. Terayama R., Bando Y., Takahashi T., Yoshida S. Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 2004, 48:91-101.
168. Tissot B., Daniel R., Place C. Interaction of the C1 complex of complement with sulfated polysaccharide and DNA probed by single molecule fluorescence microscopy. Eur. J. Biochem. 2003, 270:4714-4720.
169. Tornqvist E., Liu L., Aldskogius H., Holst H.V., Svensson M. Complement and clusterin in the injured nervous system. Neurobiol. Aging 1996, 17:695-705.
170. Tran G., Hodgkinson S., Carter N., Killingsworth M., Spicer S., Hall B. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J. Immunol. 2002, 168:4293-4300.
171. Turner M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 1996, 17:532-540.
172. van der Laan L., Ruuls S., Weber K., Lodder I., Dopp E., Dijkstra C. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 1996, 70:145-152.
173. van Lookeren Campagne M., Wiesmann C., Brown E.J. Macrophage complement receptors and pathogen clearance. Cell. Microbiol. 2007, 9:2095-2102.
174. Van Schravendijk M.R., Dwek R.A. Interaction of C1q with DNA. Mol. Immunol. 1982, 19:1179-1187.
175. Vastag M., Skopal J., Kramer J., Kolev K., Voko Z., Csonka E., Machovich R., Nagy Z. Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4. Immunobiology 1998, 199:5-13.
176. Vedeler C., Ulvestad E., Bjorge L., Conti G., Williams K., Mork S., Matre R. The expression of CD59 in normal human nervous tissue. Immunology 1994, 82:542-547.
177. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592-1603.
178. Vegh Z., Kew R.R., Gruber B.L., Ghebrehiwet B. Chemotaxis of human monocyte-derived dendritic cells to complement component C1q is mediated by the receptors gC1qR and cC1qR. Mol. Immunol. 2006, 43:1402-1407.
179. Ward P.A. Functions of C5a receptors. J. Mol. Med. (Berl.) 2009, 87:375-378.
180. Weerth S.H., Rus H., Shin M.L., Raine C.S. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol. 2003, 163:1069-1080.
181. Wells M.R., Zanakis M.F., Bernstein J.J. Blood-brain barrier disturbance and reconstitution after spinal cord hemisection in the rat. Exp. Neurol. 1978, 61:214-218.
182. Whitlow M., Ramm L., Mayer M. Penetration of C8 and C9 in the C5b-9 complex across the erythrocyte membrane into the cytoplasmic space. J. Biol. Chem. 1985, 260:998-1005.
183. Wing M.G., Zajicek J., Seilly D.J., Compston D.A., Lachmann P.J. Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology 1992, 76:140-145.
184. Woodruff T.M., Ager R.R., Tenner A.J., Noakes P.G., Taylor S.M. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med. 2010, 12:179-192.
185. Wu M.C., Brennan F.H., Lynch J.P., Mantovani S., Phipps S., Wetsel R.A., Ruitenberg M.J., Taylor S.M., Woodruff T.M. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9439-9444.
186. Yang Y., De Laporte L., Zelivyanskaya M.L., Whittlesey K.J., Anderson A.J., Cummings B.J., Shea L.D. Multiple channel bridges for spinal cord injury: cellular characterization of host response. Tissue Eng. Part A 2009, 15:3283-3295.
187. Yang J., Ahn H.N., Chang M., Narasimhan P., Chan P.H., Song Y.S. Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J. Neurochem. 2013, 124:523-535.
188. Yang K., DeAngelis R.A., Reed J.E., Ricklin D., Lambris J.D. Complement in action: an analysis of patent trends from 1976 through 2011. Adv. Exp. Med. Biol. 2013, 735:301-313.
189. Yao J., Harvath L., Gilbert D.L., Colton C.A. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 1990, 27:36-42.
190. Yonemasu K., Kitajima H., Tanabe S., Ochi T., Shinkai H. Effect of age on C1q and C3 levels in human serum and their presence in colostrum. Immunology 1978, 35:523-530.
191. Zhou W., Farrar C.A., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 2000, 105:1363-1371.
192. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.